Mallinckrodt plc (MNK) has an average broker rating of 1.04, which is interpreted as a Strong Buy, as rated by 12 equity analysts. Nonetheless, 11 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Mallinckrodt plc (MNK) : The highest level Mallinckrodt plc (MNK) is projected to reach is $115 for the short term and the lowest estimate is at $82. The consolidated price target from 12 rating analysts who initiate coverage on the stock is $93.42 and the possibility the share price can swing is $9.52.
For the current week, the company shares have a recommendation consensus of Buy. Mallinckrodt plc (NYSE:MNK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $78.76 and $78.41 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $79.51. The buying momentum continued till the end and the stock did not give up its gains. It closed at $78.98, notching a gain of 0.27% for the day. The total traded volume was 1,202,386 . The stock had closed at $78.77 on the previous day.
In a related news, Harbaugh Matthew K, CFO of Mallinckrodt Plc, executed a transaction worth $29,685 on May 10, 2016. A total of 500 shares were purchased at an average price of $59.37. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.